Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Creon IR dose-ranging study in cystic fibrosis-related pancreatic exocrine insufficiency
2014-004519-35Phase 2Completed
- Sponsor
- Abbott Laboratories
- Start
- Nov 2014
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Blood Coagulation Factors → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Insulin and Analogs → Hormones & Growth Factors → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pancreatin in exocrine pancreatic insufficiency (EPI) and cystic fibrosis (CF) (5 arms), sponsored by Abbott Laboratories. Primary endpoint: Coefficient of Fat Absorption. Started Nov 2014; status: completed.
02
Drugs
pancreatin
03
Conditions
exocrine pancreatic insufficiency (EPI)cystic fibrosis (CF)
Beyond the preview
Go deeper on 2014-004519-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004519-35.